Advaxis Has Several Catalysts in Early 2020, Starting With Data to Be Presented at Upcoming Meetings

Posted on January 30, 2020 by Medtech[y] Staff

Advaxis, Inc. (Nasdaq: ADXS), is up 15% on news that there will be three pieces of key data presented at upcoming medical meetings. Additionally, CVI Investments filed a 13G disclosing an 8.3% stake in Advaxis.

ASCO - Genitourinary Cancers Symposium February 12-15, 2020, San Francisco, California
Title: “KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab
on survival in metastatic, castration-resistant prostate cancer patients with or without
prior exposure to docetaxel”

Presenter: Dr. Mark N. Stein, Associate Professor, Division of Hematology/Oncology, Columbia University Medical Center
Abstract: 126, Poster number F6
Date: Thursday, February 13, 2020
Time: 11:30AM – 1:00 PM, 5:30PM - 6:30 PM PT
IASLC 2020 Targeted Therapies of Lung Cancer Meeting February 19-22, 2020, Santa Monica, California
Session: Immunotherapy Combinations
Title: A Phase 1 Study of ADXS-503 Alone and in Combination with Pembrolizumab in
Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung
Cancer
Presenter: Dr. Jennifer Carlisle, Assistant Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University
Date: Saturday, February 22, 2020
Time: 7:00 am PT
Immuno-oncology 360° February 26-28, 2020, New York, New York
Session: IO Novel Technologies
Title: “Clinical Updates for Advaxis’ Pipeline of Lm-based Immunotherapies in
Oncology”

Presenter: Andres A. Gutierrez MD PhD – Advaxis’ Chief Medical Officer and Executive Vice President
Date: Thursday, February 27, 2020
Time: 11:00 am ET


Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

Advaxis was over $7 in March of 2019, hitting a low of .25 in September of 2019 after offerings in July.

After announcing an offering earlier this month, the company has stated in their most recent investor presentation that they anticipate having a positive cash balance into early 2021.

Adxs Corporate Presentation Jan 2020 P025
ADXS Corporate Presentation

Additionally, ADXS-PSA, ADXS-NEO and ADXS-503 all have anticipated catalysts in the first half of 2020 making Advaxis a good company to watch as the year goes on.

Adxs Corporate Presentation Jan 2020 P026

Advaxis Corporate Presentation - January 2020

Join the conversation on the Advaxis Company Forum